Stapled Peptides Block a Cancer-Driving Protein Interaction by Enhancing Binding, Not Pre-Organization
Stapled peptides inhibited HIF-1α/p300 interaction more potently by enhancing helix formation during binding rather than in solution — challenging a core assumption in peptide drug design.
Quick Facts
What This Study Found
The standard assumption in peptide drug design is that stapling peptides into a helix in solution (the unbound state) makes them better drugs because they are pre-organized for binding. This study challenges that assumption.
Stapled peptides derived from HIF-1alpha were indeed more potent inhibitors of the HIF-1alpha/p300 protein-protein interaction. But circular dichroism (CD) spectroscopy showed they were not significantly more helical than unstapled versions when free in solution.
Molecular dynamics simulations and CD difference spectra revealed the real mechanism: stapling helped the peptides adopt the bioactive alpha-helical conformation specifically when bound to p300. The staple does not lock the helix beforehand; it enables better helix formation at the moment of binding.
This finding shifts the design paradigm: optimizing for bound-state helicity, not free-state helicity, is what matters for stapled peptide inhibitors.
Key Numbers
Dibromomaleimide stapling; improved potency; no change in unbound helicity; bound-state helix confirmed by CD and MD
How They Did This
Peptides derived from HIF-1alpha were synthesized with and without dibromomaleimide staples. Binding potency was measured using competition assays against the HIF-1alpha/p300 interaction. Circular dichroism characterized secondary structure in unbound and bound states. Molecular dynamics simulations modeled conformational behavior.
Why This Research Matters
Protein-protein interactions drive cancer, inflammation, and many diseases but are notoriously hard to drug with small molecules. Stapled peptides are a leading strategy to fill this gap. This study corrects a widespread design assumption, potentially improving how the field creates next-generation stapled peptide drugs.
The Bigger Picture
Protein-protein interactions drive cancer and inflammation but are hard to drug with small molecules. Stapled peptides are a leading strategy. This study changes how researchers design them — focusing on bound-state properties rather than solution-state pre-organization.
What This Study Doesn't Tell Us
In vitro study without cellular or animal data. Whether the improved binding potency translates to improved cellular activity is unknown. The dibromomaleimide staple is one of many stapling chemistries; results may differ with other approaches. Molecular dynamics simulations are models, not direct observations.
Questions This Raises
- ?Does this bound-state mechanism apply to stapled peptides targeting other protein interactions?
- ?Could computational tools predict bound-state helicity to guide design?
- ?What other stapling chemistries produce similar bound-state enhancement?
Trust & Context
- Key Stat:
- Bound-state helix not solution-state pre-organization, explains why stapled peptides are more potent — challenging a core assumption in peptide drug design
- Evidence Grade:
- Moderate evidence from biophysical studies. Clear mechanistic finding but tested only on one protein-protein interaction in vitro.
- Study Age:
- Published in 2020. Stapled peptide design has continued to evolve, incorporating insights from studies like this.
- Original Title:
- Stapled Peptides as HIF-1α/p300 Inhibitors: Helicity Enhancement in the Bound State Increases Inhibitory Potency.
- Published In:
- Chemistry (Weinheim an der Bergstrasse, Germany), 26(34), 7638-7646 (2020)
- Authors:
- Hetherington, Kristina, Hegedus, Zsofia, Edwards, Thomas A, Sessions, Richard B, Nelson, Adam, Wilson, Andrew J
- Database ID:
- RPEP-04853
Evidence Hierarchy
Frequently Asked Questions
What is peptide stapling?
Stapling chemically locks a peptide into a helical shape using a molecular bridge. This usually makes the peptide more stable and cell-permeable. This study found the staple also improves how the peptide binds to its target.
Why does this matter for cancer drug development?
Many cancer targets involve protein-protein interactions that traditional drugs cannot reach. Stapled peptides can block these interactions, and understanding their mechanism helps design better cancer drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04853APA
Hetherington, Kristina; Hegedus, Zsofia; Edwards, Thomas A; Sessions, Richard B; Nelson, Adam; Wilson, Andrew J. (2020). Stapled Peptides as HIF-1α/p300 Inhibitors: Helicity Enhancement in the Bound State Increases Inhibitory Potency.. Chemistry (Weinheim an der Bergstrasse, Germany), 26(34), 7638-7646. https://doi.org/10.1002/chem.202000417
MLA
Hetherington, Kristina, et al. "Stapled Peptides as HIF-1α/p300 Inhibitors: Helicity Enhancement in the Bound State Increases Inhibitory Potency.." Chemistry (Weinheim an der Bergstrasse, 2020. https://doi.org/10.1002/chem.202000417
RethinkPeptides
RethinkPeptides Research Database. "Stapled Peptides as HIF-1α/p300 Inhibitors: Helicity Enhance..." RPEP-04853. Retrieved from https://rethinkpeptides.com/research/hetherington-2020-stapled-peptides-as-hif1p300
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.